Date: 2012-01-17
Type of information: Production agreement
Compound: MGB-BP3
Company: Almac (UK) MGB Biopharma (UK)
Therapeutic area: Infectious diseases
Type agreement: production
manufacturing
Action mechanism: MGB-BP3 is a DNA minor groove binder.
Disease:
Details: MGB Biopharma and Almac’s Sciences Business Unit have entered into a collaboration where Almac will manufacture the production of their lead gram positive antibacterial compound MGB-BP3. The compound is currently in pre-clinical development with IND filing targeted for Q3 2012.
Financial terms:
Latest news:
